组织细胞髓性网状细胞增多症(HMR)又称恶性组织细胞增多病(MH),曾被描述为慢淋、急粒、急粒单、毛细胞性白血病、何杰金氏病、非何杰金淋巴瘤和胃癌终末前的并发症。本文复习文献上已报道的17例终末为HMR的急淋(ALL)患者,有T细胞标记、纵隔肿块或初次白细胞计数极度增高者提示为了细胞ALL。 17例患ALL和HMR的病人中男性9例,女性4例,4例末指明性別与年龄。除4例(25—54岁)外为儿童(2—17岁)。全部病例均因ALL接受化疗,至少6例也接受颅或脊髓预防性照射。几乎所有的患者对抗白血病治疗有短暂的疗效,但于数月内发生HMR,多表现为全血细胞减少和肝、脾、淋巴结 Histocyte myelocytosis (HMR), also known as malignant histiocytosis (MH), has been described as CLL, acute pellet, acute myelomonocytic leukemia, Hodgkin’s disease, non-what Jie Jin lymphoma and gastric cancer complications before the terminal. This review of the literature has been reported in 17 cases of HMR end of the disease (ALL) patients with T cell markers, mediastinal mass or initial high white blood cell count were prompted for the cell ALL. Of the 17 patients with ALL and HMR, 9 were males and 4 were females, and the last 4 were sex and age. Children (2-17 years) except 4 (25-54 years). ALL patients received chemotherapy for ALL, and at least 6 patients also received cranial or spinal prophylactic irradiation. Almost all patients have a short-term response to leukemia treatment but develop HMR within months, mostly with pancytopenia and liver, spleen and lymph nodes